Distinguishing Clinicopathologic Features of Patients with V600E and V600K BRAF-Mutant Metastatic Melanoma
about
Resistant mechanisms to BRAF inhibitors in melanomaDabrafenib: a new opportunity for the treatment of BRAF V600-positive melanomaMedical management of malignant melanomaMelanoma: oncogenic drivers and the immune systemTherapy for BRAFi-Resistant Melanomas: Is WNT5A the Answer?Multiple Molecular Pathways in Melanomagenesis: Characterization of Therapeutic TargetsSafety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label studyBRAF-V600 mutations have no prognostic impact in stage IV melanoma patients treated with monochemotherapyCopy Number Changes Are Associated with Response to Treatment with Carboplatin, Paclitaxel, and Sorafenib in MelanomaLong Term Survival and Continued Complete Response of Vemurafenib in a Metastatic Melanoma Patient with BRAF V600K Mutation.A graph theoretic approach to utilizing protein structure to identify non-random somatic mutations.BRAF mutations: signaling, epidemiology, and clinical experience in multiple malignancies.Development and validation of a clinical trial patient stratification assay that interrogates 27 mutation sites in MAPK pathway genes.Correlation of somatic mutations and clinical outcome in melanoma patients treated with Carboplatin, Paclitaxel, and sorafenibMolecular alterations in clinical stage III cutaneous melanoma: Correlation with clinicopathological features and patient outcome.Reflectance confocal microscopy features of BRAF V600E mutated thin melanomas detected by immunohistochemistryCorrelation of BRAF and NRAS mutation status with outcome, site of distant metastasis and response to chemotherapy in metastatic melanoma.Understanding the biology of melanoma and therapeutic implicationsThe clinical response to vemurafenib in a patient with a rare BRAFV600DK601del mutation-positive melanoma.Complete loss of PTEN protein expression correlates with shorter time to brain metastasis and survival in stage IIIB/C melanoma patients with BRAFV600 mutationsMolecular characterization and patient outcome of melanoma nodal metastases and an unknown primary site.Comparative evaluation of the new FDA approved THxID™-BRAF test with High Resolution Melting and Sanger sequencingEffect of dabrafenib on melanoma cell lines harbouring the BRAF(V600D/R) mutations.Dabrafenib and its potential for the treatment of metastatic melanoma.Genotyping of cutaneous melanoma.BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.Beyond BRAF(V600): clinical mutation panel testing by next-generation sequencing in advanced melanomaTargeted BRAF inhibition impacts survival in melanoma patients with high levels of Wnt/β-catenin signaling.Whole exome sequencing identifies a recurrent RQCD1 P131L mutation in cutaneous melanomaCXCR3 signaling in BRAFWT melanoma increases IL-8 expression and tumorigenicity.KIAA1549: BRAF Gene Fusion and FGFR1 Hotspot Mutations Are Prognostic Factors in Pilocytic Astrocytomas.Comparison between two widely used laboratory methods in BRAF V600 mutation detection in a large cohort of clinical samples of cutaneous melanoma metastases to the lymph nodes.Epithelioid GBMs show a high percentage of BRAF V600E mutation.Tumor cellularity as a quality assurance measure for accurate clinical detection of BRAF mutations in melanoma.BRAF pyrosequencing analysis aided by a lookup table.A Network Meta-Analysis of Short and Long-Term Efficacy of Targeted Therapy With Single or Double-Drug Regimens in the Treatment of Stage III/IV Malignant Melanoma Based on 16 Randomized Controlled Trials.Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanomaThe molecular pathology of melanoma: an integrated taxonomy of melanocytic neoplasia.Rare BRAF mutations in melanoma patients: implications for molecular testing in clinical practice.Oncogenic BRAF-Mediated Melanoma Cell Invasion.
P2860
Q26739717-90EC691E-3737-413B-8C1E-88F0D4E2DFE4Q26745933-B9DC8C49-A02D-42F0-A022-B130E0414D9DQ26773302-390DBA56-F034-4217-B206-92DE1847B3AAQ26775598-E2FA3304-746D-4B60-83F4-93F23626A92DQ26782222-537680D2-9C19-446B-B839-364D9EEC1B02Q26795735-4242C063-2FE4-4D82-B21E-86307F07D688Q27276774-8853D371-6158-4AAF-8BAF-303A1F6B84D3Q27852927-DA9863F4-A8A1-46C5-8EF1-0F5CC94F7556Q27853202-3864B668-3112-4516-9479-8311031B31A5Q27853361-EB5BB594-BA2E-4B77-B97B-A9DE601B9AB7Q30360645-30D87F3A-F233-4D3D-A2CE-BC6401FD9DDDQ30458424-387662C9-CE14-47C9-A291-E4D2A8E8DF1FQ31132555-88F49EB7-E80C-405E-B391-7958CDB34F55Q33758211-1FAD909C-A711-47A5-9D36-A10A71679964Q33778554-EDFF10E3-ABD3-4210-AD03-2791BD37D143Q33852985-4B7DD069-46C0-47E6-A883-7DAB2338AE62Q33918101-9F4EA7E8-B88D-4337-B7D8-C76188160363Q33978378-143EEC9D-9BD9-4F1D-B506-85E583F50D91Q34316552-014B4176-8C3C-4E88-A275-F3DF837272A2Q34438555-417CBDE7-5A94-4E60-84F1-F5FD52707AB6Q34446657-D3CC95D2-0A4E-43BF-BE4D-2FB460C07DF0Q34469532-7332487D-1DB8-4456-9DD8-BE040FAB239FQ34547540-06E1FB70-8558-464F-80D5-4A7815F92D3AQ34646614-135AF1AC-1999-419F-94F6-9E194FCDDD4BQ34667738-C0267A61-3C7F-4835-8EAC-74DFA1073D5CQ34667825-0CF2A2F2-1C40-4DA1-954C-1476680611E9Q34898560-C9B6DE5E-6547-4A42-BC59-66D176A1D91BQ35148036-BE3EF75D-5BB6-4B42-94AC-731E7A42B5AFQ35176032-1E580D9A-A39B-426F-BC6B-03A6A1AE6AE2Q35583851-FB03EA5F-840B-4E15-AE2F-5C63B30E4346Q35751428-4A290052-882B-49B3-8F8D-284868E1B4F4Q36014476-1ECF4287-F773-4D12-82F2-6FF5C3FF1BB7Q36175648-49BF9C88-A156-4036-A5A5-706D403FB1FEQ36276146-41E267F6-9F43-472D-A9C7-DD6D7C621686Q36276150-8FCE3C0E-802D-49E2-82A6-3A1AD6D5BB62Q36409040-81AAA32A-C174-4AB0-97C5-FFFDDE9078B6Q36561655-6970833F-7537-4349-AC8A-9C5C77A7CB29Q36798179-5361439D-15F6-43D0-8484-AE0F29EF9391Q36896131-7D8A6F5F-7E33-46C2-A911-150073A40D9EQ36957578-3D3F14CA-0034-449B-972B-F3E070C41176
P2860
Distinguishing Clinicopathologic Features of Patients with V600E and V600K BRAF-Mutant Metastatic Melanoma
description
im April 2012 veröffentlichter wissenschaftlicher Artikel
@de
scientific article published on 24 April 2012
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована у квітні 2012
@uk
name
Distinguishing Clinicopatholog ...... RAF-Mutant Metastatic Melanoma
@en
Distinguishing Clinicopatholog ...... RAF-Mutant Metastatic Melanoma
@nl
type
label
Distinguishing Clinicopatholog ...... RAF-Mutant Metastatic Melanoma
@en
Distinguishing Clinicopatholog ...... RAF-Mutant Metastatic Melanoma
@nl
prefLabel
Distinguishing Clinicopatholog ...... RAF-Mutant Metastatic Melanoma
@en
Distinguishing Clinicopatholog ...... RAF-Mutant Metastatic Melanoma
@nl
P2093
P50
P1476
Distinguishing clinicopatholog ...... RAF-mutant metastatic melanoma
@en
P2093
John F Thompson
Julie R Howle
Lauren E Haydu
Lydia Visintin
Matteo S Carlino
P304
P356
10.1158/1078-0432.CCR-12-0052
P407
P577
2012-04-24T00:00:00Z